Annexon, Inc. (ANNX) stock
ANNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.92−0.05 (-1.26%)
Close on Nov 13, 2026Market cap $801.42MP/E –Yield 0.00%
Annexon ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Annexon's ebitda for the twelve months ending Sep 30, 2026 was -$203.63M. For fiscal 2025 it was -$214.24M. The highest annual figure on record is -$32.03M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$214.24M | – |
| FY2024 | Dec 31, 2024 | -$151.92M | – |
| FY2023 | Dec 31, 2023 | -$141.58M | – |
| FY2022 | Dec 31, 2022 | -$143.49M | – |
| FY2021 | Dec 31, 2021 | -$128.57M | – |
| FY2020 | Dec 31, 2020 | -$62.80M | – |
| FY2019 | Dec 31, 2019 | -$32.03M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$51.71M | – |
| Q2 FY2026 | Jun 30, 2026 | -$56.69M | – |
| Q1 FY2026 | Mar 31, 2026 | -$45.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$49.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$56.47M | – |
| Q2 FY2025 | Jun 30, 2025 | -$51.19M | – |
| Q1 FY2025 | Mar 31, 2025 | -$56.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$51.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$38.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$40.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$36.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$35.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$36.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$34.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$36.95M | – |
| Q3 FY2021 | Sep 30, 2021 | -$35.12M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.84M | – |
| Q1 FY2021 | Mar 31, 2021 | -$25.66M | – |
| Q4 FY2020 | Dec 31, 2020 | -$22.92M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.46M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.11M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.33M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.00M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.94M | – |
See a number that looks wrong?